Nlsp recent news on 09/19/2024

Here is some news about Nlsp on 09/19/2024: 1. **Development Focus**: NLS Pharmaceutics AG is concentrating on the development of treatments for rare sleep disorders like narcolepsy and idiopathic hypersomnia, as well as neurodevelopmental disorders such as ADHD. Their lead product candidates include Quilience for narcolepsy and Nolazol for ADHD, reflecting their commitment to addressing these conditions. 2. **Product Pipeline**: The company is also working on NLS-4 for chronic fatigue associated with Long-COVID, NLS-3 for ADHD, NLS-8 for improved scopolamine-induced amnesia, NLS-11 for muscarinic M1, M2, M3 receptor antagonist, and NLS-12 for muscarinic M4 receptor antagonist. This diverse pipeline showcases their innovative approach to addressing various neurological disorders. 3. **Licensing Agreements**: NLS Pharmaceutics AG has entered into licensing agreements with NeuroLife-Sciences SAS for mazindol treatment of ADHD and with Eurofarma Laboratorios S.A. for the commercialization and distribution of Nolazol in Latin America. These partnerships are instrumental in expanding their reach and impact in the treatment of ADHD. In conclusion, NLS Pharmaceutics AG is actively engaged in the development of novel therapies for rare and complex neurological disorders, with a particular focus on narcolepsy, idiopathic hypersomnia, and ADHD. Their robust product pipeline and strategic partnerships underscore their commitment to addressing unmet medical needs in these areas.